Integrin inhibitors as a therapeutic agent for ovarian cancer

Journal of Oncology

Volumn , Issue , 2012, Pages

  Sawada, Kenjiro ^a   Ohyagi Hara, Chifumi ^a   Kimura, Tadashi ^a   Morishige, Ken Ichirou ^b  

^a OSAKA UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CILENGITIDE; ETARACIZUMAB; INTEGRIN; INTEGRIN INHIBITOR; INTETUMUMAB; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VOLOCIXIMAB;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER SCREENING; CELL MIGRATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; LOW DRUG DOSE; METASTASIS; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84855604996     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/915140     Document Type: Review

References (42)

1. Cannistra S. A., Cancer of the ovary The New England Journal of Medicine 2004 351 24 2519 2565
2. Jin H., Varner J., Integrins: roles in cancer development and as treatment targets British Journal of Cancer 2004 90 3 561 565 (Pubitemid 38297190)
3. Desgrosellier J. S., Cheresh D. A., Integrins in cancer: biological implications and therapeutic opportunities Nature Reviews Cancer 2010 10 1 9 22
4. Guo W., Giancotti F. G., Integrin signalling during tumour progression Nature Reviews Molecular Cell Biology 2004 5 10 816 826 (Pubitemid 39336275)
5. Hynes R. O., Integrins: bidirectional, allosteric signaling machines Cell 2002 110 6 673 687 (Pubitemid 35283958)
6. Wang Z., Chui W. K., Ho P. C., Integrin targeted drug and gene delivery Expert Opinion on Drug Delivery 2010 7 2 159 171
7. Stupp R., Ruegg C., Integrin inhibitors reaching the clinic Journal of Clinical Oncology 2007 25 13 1637 1638 (Pubitemid 46797938)
8. Makrilia N., Kollias A., Manolopoulos L., Syrigos K., Cell adhesion molecules: role and clinical significance in cancer Cancer Investigation 2009 27 10 1023 1037
9. Nam J. M., Chung Y., Hsu H. C., Park C. C., 1 integrin targeting to enhance radiation therapy International Journal of Radiation Biology 2009 85 11 923 928
10. Sethi T., Rintoul R. C., Moore S. M., MacKinnon A. C., Salter D., Choo C., Chilvers E. R., Dransfield I., Donnelly S. C., Strieter R., Haslett C., Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo Nature Medicine 1999 5 6 662 668 (Pubitemid 29289430)
11. Hodkinson P. S., Elliott T., Wong W. S., Rintoul R. C., Mackinnon A. C., Haslett C., Sethi T., ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through 1 integrin-dependent activation of PI3-kinase Cell Death and Differentiation 2006 13 10 1776 1788 (Pubitemid 44390864)
12. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
13. Bast R. C. Jr., Hennessy B., Mills G. B., The biology of ovarian cancer: new opportunities for translation Nature Reviews Cancer 2009 9 6 415 428
14. Buys S. S., Partridge E., Black A., Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial JAMA 2011 305 22 2295 2303
15. Bristow R. E., Tomacruz R. S., Armstrong D. K., Trimble E. L., Montz F. J., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis Journal of Clinical Oncology 2002 20 5 1248 1259 (Pubitemid 34177431)
16. Shin K. K., Chi D. S., Maximal cytoreductive effort in epithelial ovarian cancer surgery Journal of Gynecologic Oncology 2010 21 2 75 80
17. Lengyel E., Ovarian cancer development and metastasis American Journal of Pathology 2010 177 3 1053 1064
18. Jazaeri A. A., Slack-Davis J. K., The promise of antiangiogenic therapy for ovarian cancer Cancer Biology and Therapy 2009 8 23 2273 2274
19. Banerjee S., Gore M., The future of targeted therapies in ovarian cancer Oncologist 2009 14 7 706 716
20. Sawada K., Mitra A. K., Radjabi A. R., Bhaskar V., Kistner E. O., Tretiakova M., Jagadeeswaran S., Montag A., Becker A., Kenny H. A., Peter M. E., Ramakrishnan V., Yamada S. D., Lengyel E., Loss of E-cadherin promotes ovarian cancer metastasis via 5-integrin, which is a therapeutic target Cancer Research 2008 68 7 2329 2339 (Pubitemid 351521807)
21. Casey R. C., Burleson K. M., Skubitz K. M., Pambuccian S. E., Oegema T. R., Ruff L. E., Skubitz A. P. N., 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids American Journal of Pathology 2001 159 6 2071 2080 (Pubitemid 33104261)
22. Strobel T., Cannistra S. A., Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro Gynecologic Oncology 1999 73 3 362 367 (Pubitemid 29272856)
23. Moser T. L., Pizzo S. V., Bafetti L. M., Fishman D. A., Stack M. S., Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the 2 1 integrin International Journal of Cancer 1996 67 5 695 701 (Pubitemid 26300989)
24. Slack-Davis J. K., Atkins K. A., Harrer C., Daniel Hershey E., Conaway M., Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis Cancer Research 2009 69 4 1469 1476
25. Ahmed N., Pansino F., Clyde R., Murthi P., Quinn M. A., Rice G. E., Agrez M. V., Mok S., Baker M. S., Overexpression of v 6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade Carcinogenesis 2002 23 2 237 244 (Pubitemid 34223999)
26. Kaur S., Kenny H. A., Jagadeeswaran S., Zillhardt M. R., Montag A. G., Kistner E., Yamada S. D., Mitra A. K., Lengyel E., 3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer American Journal of Pathology 2009 175 5 2184 2196
27. Reynolds A. R., Hart I. R., Watson A. R., Welti J. C., Silva R. G., Robinson S. D., Da Violante G., Gourlaouen M., Salih M., Jones M. C., Jones D. T., Saunders G., Kostourou V., Perron-Sierra F., Norman J. C., Tucker G. C., Hodivala-Dilke K. M., Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors Nature Medicine 2009 15 4 392 400
28. Khalili P., Arakelian A., Chen G., Plunkett M. L., Beck I., Parry G. C., Doate F., Shaw D. E., Mazar A. P., Rabbani S. A., A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo Molecular Cancer Therapeutics 2006 5 9 2271 2280 (Pubitemid 44530464)
29. Landen C. N., Kim T. J., Lin Y. G., Merritt W. M., Kamat A. A., Han L. Y., Spannuth W. A., Nick A. M., Jennnings N. B., Kinch M. S., Tice D., Sood A. K., Tumor-selective response to antibody-mediated targeting of v 3 integrin in ovarian cancer Neoplasia 2008 10 11 1259 1267
30. Bellone M., Cocco E., Varughese J., Expression of V-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti- V-integrin antibody International Journal of Gynecological Cancer 2011 21 6 1084 1090
31. Avraamides C. J., Garmy-Susini B., Varner J. A., Integrins in angiogenesis and lymphangiogenesis Nature Reviews Cancer 2008 8 8 604 617
32. Bell-McGuinn K. M., Matthews C. M., Ho S. N., A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer Gynecologic Oncology 2011 121 2 273 279
33. Donate F., Parry G. C., Shaked Y., Hensley H., Guan X., Beck I., Tel-Tsur Z., Plunkett M. L., Manuia M., Shaw D. E., Kerbel R. S., Mazar A. P., Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth Clinical Cancer Research 2008 14 7 2137 2144 (Pubitemid 351551126)
34. Cianfrocca M. E., Kimmel K. A., Gallo J., Cardoso T., Brown M. M., Hudes G., Lewis N., Weiner L., Lam G. N., Brown S. C., Shaw D. E., Mazar A. P., Cohen R. B., Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2), a beta integrin antagonist, in patients with solid tumours British Journal of Cancer 2006 94 11 1621 1626 (Pubitemid 43924924)
35. Brooks P. C., Stromblad S., Klemke R., Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin The Journal of Clinical Investigation 1995 96 4 1815 1822
36. Posey J. A., Khazaeli M. B., DelGrosso A., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer Cancer Biother Radiopharm 2001 16 2 125 132 (Pubitemid 34121636)
37. Trikha M., Zhou Z., Nemeth J. A., Chen Q., Sharp C., Emmell E., Giles-Komar J., Nakada M. T., CNTO 95, a fully human monoclonal antibody that inhibits v integrins, has antitumor and antiangiogenic activity in vivo International Journal of Cancer 2004 110 3 326 335 (Pubitemid 38649882)
38. Chen Q., Manning C. D., Millar H., McCabe F. L., Ferrante C., Sharp C., Shahied-Arruda L., Doshi P., Nakada M. T., Anderson G. M., CNTO 95, a fully human anti v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells Clinical and Experimental Metastasis 2008 25 2 139 148
39. Martin P. L., Jiao Q., Cornacoff J., Hall W., Saville B., Nemeth J. A., Schantz A., Mata M., Jang H., Fasanmade A. A., Anderson L., Graham M. A., Davis H. M., Treacy G., Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti- v integrin monoclonal antibody, despite widespread tissue binding Clinical Cancer Research 2005 11 19 6959 6965 (Pubitemid 41428754)
40. Mullamitha S. A., Ton N. C., Parker G. J., Jackson A., Julyan P. J., Roberts C., Buonaccorsi G. A., Watson Y., Davies K., Cheung S., Hope L., Valle J. W., Radford J. A., Lawrance J., Saunders M. P., Munteanu M. C., Nakada M. T., Nemeth J. A., Davis H. M., Jiao Q., Prabhakar U., Lang Z., Corringham R. E., Beckman R. A., Jayson G. C., Phase I evaluation of a fully human anti- v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors Clinical Cancer Research 2007 13 7 2128 2135 (Pubitemid 46649882)
41. Nabors L. B., Mikkelsen T., Rosenfeld S. S., Hochberg F., Akella N. S., Fisher J. D., Cloud G. A., Zhang Y., Carson K., Wittemer S. M., Colevas A. D., Grossman S. A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma Journal of Clinical Oncology 2007 25 13 1651 1657 (Pubitemid 46797943)
42. Reardon D. A., Fink K. L., Mikkelsen T., Cloughesy T. F., O'Neill A., Plotkin S., Glantz M., Ravin P., Raizer J. J., Rich K. M., Schiff D., Shapiro W. R., Burdette-Radoux S., Dropcho E. J., Wittemer S. M., Nippgen J., Picard M., Nabors L. B., Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme Journal of Clinical Oncology 2008 26 34 5610 5617